Eton Pharmaceuticals, Inc.

ETON

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001710340

SEC filings (opens in a new tab)

In the last 90 days, Eton Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 164 institutions reported holding it in 13F filings for Q2 2026, worth $722.6M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 11, 2026: $1.97B
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $16.2M in total: 5
13F holdersQ2 2026, +49 vs. previous quarter: 164
13F valueReported value at the end of Q2 2026: $722.6M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $80.0M; +104.9% year over year
Net income, FY2025: -$4.60M; No comparable prior period
Free cash flow, FY2025: $10.2M; +980.7% year over year
Revenue, Q3 FY2026: $57.9M; +157.9% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $4.60M (5.8% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 1.99M; Shares sold short
Change: +42.8K; +2.2% vs. previous
Days to cover: 5.43; At average daily volume

Superinvestors holding ETON, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ETON at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Eton Pharmaceuticals, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Nov 10, 2026 (view filing)6:21 PM ET	Nov 10	Same day	Casamento Charles JDirector	SSale	−80.6K	$66.35	−$5.35M	−100.0%0 after	5 lots
Oct 6, 2026 (view filing)4:49 PM ET	Oct 6	Same day	Krempa DavidChief Business Officer	SSale	−4.17K	$55.07	−$229.4K	−8.8%43.4K after
Aug 31, 2026 (view filing)4:06 PM ET	Aug 28	3 days	Maier Paul VDirector	SSale	−50.0K	$59.07	−$2.95M	−45.6%59.7K after	Amended3 lots
Aug 24, 2026 (view filing)5:19 PM ET	Aug 24	Same day	Krempa DavidChief Business Officer	SSale	−25.0K	$65.07	−$1.63M	−40.3%37.0K after
Aug 20, 2026 (view filing)6:26 PM ET	Aug 19-20	1 day	Brynjelsen SeanPresident & CEO	SSale	−100.0K	$60.88	−$6.09M	−9.4%961.2K after	4 lots
Jul 17, 2026 (view filing)7:12 PM ET	Jul 14	3 days	Opaleye Management Inc.10% Owner	SSaleCommon Stock, par value $0.001 per share	−28.3K	$37.54	−$1.06M	−41.4%40.0K after	Amended2 lots
Jul 7, 2026 (view filing)6:29 PM ET	Jul 2-7	5 days	Opaleye Management Inc.10% Owner	SSaleCommon Stock, par value $0.001 per share	−126.7K	$37.64	−$4.77M	−70.4%53.3K after	5 lots
Jun 17, 2026 (view filing)	Jun 17	Same day	Adams Jennifer McKieDirector	SSale	−50.0K	$32.48	−$1.62M	−100.0%0 after
May 29, 2026 (view filing)	May 28	1 day	Brynjelsen SeanPresident & CEO	SSale	−120.0K	$31.88	−$3.83M	−12.6%833.7K after	2 lots
May 27, 2026 (view filing)	May 22-27	5 days	Krempa DavidChief Business Officer	SSale	−100.0K	$32.30	−$3.23M	−79.8%25.2K after	5 lots

Top 10 13F holders, Q2 2026

See all 164 holders

The largest institutional positions in Eton Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding ETON in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Opaleye Management Inc.	2,860,000	$103.5M	9.38%	00.0%	Unchanged
EcoR1 Capital, LLC	2,171,938	$78.6M	3.90%	00.0%	Unchanged
BlackRock, Inc.	1,895,833	$68.6M	0.00%	+178,547+10.4%	Added
Nantahala Capital Management, LLC	1,175,951	$42.6M	2.57%	00.0%	Unchanged
Vanguard Capital Management LLC	976,570	$35.4M	0.00%	−17,519−1.8%	Reduced
Morgan Stanley	767,972	$27.8M	0.00%	+290,015+60.7%	Added
State Street Corp	701,786	$25.4M	0.00%	+171,571+32.4%	Added
Geode Capital Management, LLC	652,303	$23.6M	0.00%	+74,637+12.9%	Added
Oberweis Asset Management Inc	501,600	$18.2M	0.38%	+62,300+14.2%	Added
National Philanthropic Trust	492,112	$17.8M	0.26%	00.0%	Unchanged

Holders of 5% or more of ETON

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Eton Pharmaceuticals, Inc..

Largest holders of ETON from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Opaleye Management Inc.	13G/A	8.54%2.44M shares	–	Jun 17, 20216 filings	Nov 6, 2026	SEC
EcoR1 Capital, LLC	13G/A	7.70%1.98M shares	–	Dec 9, 20242 filings	Feb 14, 2025	SEC
BlackRock, Inc.	13G/A	6.90%1.88M shares	+1.20 ppfrom 5.70%	Jul 17, 20252 filings	Jul 28, 2026	SEC